Switching GLP-1 Meds: Dose Maps and Real Talk

Four months on Wegovy, down 9% of body weight, and your Reddit feed just surfaced someone on Mounjaro who dropped 22% in the same window. You close the app, then open it again. Or your insurer flipped formularies mid-year and your copay tripled between one refill and the next — $25 to $375, overnight. Or your doctor brought up Foundayo, the oral GLP-1 that doesn't demand a 30-minute fasting ritual, and now you're weighing whether a pill makes sense when you've already white-knuckled through the nausea phase once.

Whatever's driving the conversation, switching between GLP-1 medications is the single most common question in obesity-medicine clinics right now. It's also one of the least well-explained.

Here's the uncomfortable truth: there's no FDA-approved switching protocol. No head-to-head switching RCT exists as of May 2026. What we do have is a growing body of real-world data, clinical consensus from prescribers who've managed hundreds of these transitions, and a deep well of patient-reported experience from communities like r/GLP1 and r/Zepbound. That's what this guide rests on.

Why people switch (and when it actually makes sense)

The reasons cluster into five buckets:

1. Plateau or underwhelming response. You've held a stable dose for 12+ weeks and weight loss has flatlined below your clinical target. About 13% of patients on semaglutide 2.4 mg are classified as non-responders — under 5% body weight loss at 68 weeks in STEP 1. If that's you, a different molecule with a different receptor profile may unlock what semaglutide couldn't.

2. Side effects that won't fade. Persistent nausea, constipation, or gastroparesis-like symptoms that don't resolve with dose adjustment or time. Some people tolerate one molecule far better than the other — the GLP-1/GIP dual mechanism in tirzepatide hits the gut differently than GLP-1 alone.

3. Insurance or cost disruption. Your plan dropped coverage, your prior authorization got denied on renewal, or the compounded semaglutide you were sourcing got pulled in the 2025–2026 FDA crackdown. Roughly 34% of commercial plans still exclude anti-obesity medications entirely.

4. Stronger data on a different drug. SURMOUNT-1 showed tirzepatide 15 mg achieving −20.9% body weight over 72 weeks, compared to semaglutide 2.4 mg at −14.9% over 68 weeks in STEP 1. Real-world data suggests roughly 60–65% of semaglutide-to-tirzepatide switchers see additional weight loss.

5. Ditching the needle. Oral semaglutide (now available as Oral Wegovy at 25 mg and 50 mg since January 2026) and orforglipron (Foundayo, FDA-approved April 2026) both offer injection-free paths. For patients with needle anxiety or injection-site reactions, this alone can be reason enough.

Not every switch needs a clinical justification. Sometimes a better option simply showed up.

There's no clean 1:1 dose conversion

This is where things get tangled. Semaglutide and tirzepatide are different molecules with different receptor profiles — GLP-1 only versus GLP-1 plus GIP dual agonist. No published equivalence table exists. The dose ladders don't map neatly onto each other, and prescribers have to rely on clinical judgment rather than a formula.

The titration schedules, side by side:

The practical upshot: when you switch between molecules, you almost always restart near the bottom of the new drug's ladder. Your body has to recalibrate to a different receptor profile, a different half-life, and a different GI tolerance curve. Four months of nausea conditioning on semaglutide doesn't transfer to tirzepatide. The receptors don't care about your history.

Five common switches, mapped

Saxenda to Wegovy

The daily-to-weekly upgrade. Most people making this move in 2026 are chasing efficacy — Saxenda (liraglutide) produces roughly 8% weight loss at its ceiling, while Wegovy (semaglutide 2.4 mg) hits about 15% on average. Stop Saxenda on a Tuesday, start Wegovy 0.25 mg the following week. Full restart at the bottom of the ladder. GI adjustment is typical but often milder than your first Saxenda week — your gut already knows what a GLP-1 agonist feels like, even if the molecule is new.

Ozempic to Wegovy

Same molecule, different label. Ozempic tops out at 2 mg for type 2 diabetes; Wegovy goes to 2.4 mg for obesity. If you're on Ozempic 0.5 mg, your doctor can match you directly to Wegovy 0.5 mg — no restart necessary. If you're at Ozempic 1 mg or above, the mapping becomes physician-directed. The main motivation: Wegovy carries the obesity indication and now the cardiovascular indication from SELECT, which matters for insurance coding and prior authorization.

Wegovy to Mounjaro or Zepbound

Different molecule. This is the high-traffic switch — the one with the most Reddit threads, the most clinic questions, and the most misunderstanding. There's no direct dose conversion. Regardless of where you sit on Wegovy, you restart at tirzepatide 2.5 mg. Even if you've been on 2.4 mg semaglutide for six months. Your GI side effects will likely restart too — nausea in the first 7–10 days is common. The upside that pulls most switchers through: that 60–65% chance of additional weight loss beyond what semaglutide delivered.

"Switched from Wegovy 2.4 to Zepbound 2.5. First two weeks felt like starting over — the nausea was back, appetite came roaring in before the tirz kicked in. By week 4 on 5 mg I was already past where semaglutide had me. Worth it, but nobody told me about the gap weeks." — r/Zepbound, March 2026

Injectable semaglutide to oral semaglutide

Since January 2026, Oral Wegovy is available at 25 mg and 50 mg doses. The rough equivalence: 14 mg oral approximates 0.5 mg injectable, and 50 mg oral approximates 2.4 mg injectable. "Rough" is doing heavy lifting in that sentence — oral bioavailability of semaglutide runs around 1%, which is why oral doses are measured in tens of milligrams while injectable doses are measured in fractions. The titration ladder runs 3 → 7 → 14 → 25 → 50 mg in 4-week steps. Your doctor may start you partway up based on your injectable dose history.

Any GLP-1 to Foundayo (orforglipron)

The newest entry, FDA-approved April 2026. Foundayo is a small-molecule GLP-1 agonist — not a peptide like semaglutide or tirzepatide — which means it's a daily pill at $149/month with no food restrictions and no fasting window. The ATTAIN trial showed −7.9% to −9.4% body weight loss over 26 weeks. Less than semaglutide or tirzepatide at full dose, but the value equation is different: cheaper, simpler, no cold-chain storage, and available without insurance battles for many patients. Titration starts at 12 mg, escalating every 2 weeks through 24, 36, 48, and 60 mg, with a ceiling of 72 mg.

The gap weeks nobody warns you about

When you switch between different molecules, there's a 1–3 week window where you're between drugs. You've stopped the old one — or it's washing out — and the new one hasn't reached steady-state plasma levels. Your appetite control feels like someone flipped a switch off. The food noise comes back like a radio you forgot was on.

Normal. Not failure.

Semaglutide has a half-life of about 7 days. Take your last Wegovy shot on Monday and it takes roughly 5 weeks for the drug to fully clear. But the subjective appetite-suppressing effect fades faster — most people report food noise returning within 10–14 days of their last injection. If you're simultaneously starting tirzepatide at its lowest dose, you haven't built enough plasma concentration to compensate yet. It's a pharmacokinetic gap, and it's temporary.

"The two weeks between stopping Wegovy and feeling Zepbound kick in were honestly rough. My food noise came back full volume. I gained 4 lbs of water weight and panicked. My doctor said just ride it out. She was right — by week 3 on Zepbound I was fine." — r/GLP1, February 2026

Some prescribers handle this by overlapping the last week of the old drug with the first dose of the new one. Others prefer a clean break. Worth raising with your doctor before the switch, not after.

GI side effects come back — plan for round two

The data consistently shows switching to a new GLP-1 molecule resets your GI tolerance. Even if you breezed through Wegovy's titration with minimal nausea, tirzepatide may hit differently. The reverse is also true.

The typical pattern:

• Week 1–2 on the new drug: nausea returns, appetite swings, some constipation or loose stools
• Week 3–4: symptoms start settling as plasma levels stabilize
• Week 5–8: most people report side effects fading to background noise

Severity is generally less intense than your first-ever GLP-1 experience, but it's not zero. Stock up on the same toolkit that got you through round one — smaller meals, steady hydration, ginger chews, and patience. The unromantic toolkit. If symptoms are severe or persist past 8 weeks, that's a conversation for your prescriber.

Your pre-switch checklist

Not every item applies to every switch, but running through the list saves a lot of downstream pain:

• Confirm insurance coverage for the new drug before stopping the old one. Prior authorization is typically required per medication. A Wegovy PA doesn't carry over to Zepbound.
• Check the formulary tier. Out-of-pocket costs can shift dramatically. Medicare GLP-1 coverage starts July 1, 2026 at a $50/month copay — if you're 65+, the timing of your switch matters a lot.
• Secure the prescription and verify pharmacy stock. Supply disruptions are less severe than the 2024 shortages but still happen for specific dose strengths.
• Ask about overlap vs. clean break. Does your prescriber want you to take the last dose of Drug A and start Drug B the same week, or wait?
• Plan for the gap weeks. Meal prep, schedule lighter social commitments around food. The hunger rebound is real but temporary.
• Get baseline labs. A1c, lipid panel, kidney function. A fresh starting point helps your new prescriber calibrate.
• Keep tracking. If you're using Blueshot or another GLP-1 tracker, log everything through the transition. That data becomes leverage for dose-adjustment conversations later.

Navigating the insurance maze

Every switch triggers a new prior authorization cycle. Here's the cost landscape as of mid-2026:

The compounded semaglutide market is contracting fast. The FDA ended enforcement discretion for compounders in late 2025, and patients who were paying $200–$400/month for compounded product are being pushed toward brand-name options or alternatives like Foundayo. If that's your situation, the $149/month Foundayo price point deserves a serious look — it's less potent than full-dose semaglutide or tirzepatide, but it's a fraction of brand cash-pay pricing and doesn't require prior authorization or insurance approval.

Switching doesn't erase your progress

One misconception worth dismantling: switching GLP-1 medications isn't the same as starting over. The weight you've lost doesn't reappear because you changed molecules. Your metabolic improvements — better insulin sensitivity, improved lipid profiles, reduced inflammatory markers — don't vanish overnight. The data on what happens when you stop GLP-1s entirely is sobering, but switching is a different situation. You're not stopping. You're changing tools.

What does reset: your GI tolerance and your position on the titration ladder. Expect to spend 8–16 weeks climbing back to a therapeutic dose on the new medication. Budget that runway into your expectations.

Questions worth bringing to your next appointment

If you're weighing a switch, these six questions tend to produce the most actionable answers:

1. Based on my response to [current drug] so far, what additional benefit would you expect from [new drug]?
2. Should I overlap my last dose with the first dose of the new medication, or do a clean washout?
3. What starting dose makes sense, and how fast will we titrate?
4. Will my insurance require a new PA? Can we file before I run out of current supply?
5. If the new medication doesn't work, can I go back without restarting the PA process?
6. Are there drug interactions with the new medication that weren't relevant before?

Print them. Bring the list. A 15-minute appointment evaporates faster than you'd expect, and these questions cover the gaps most patients don't think to ask until they're already mid-transition.

Where the options stand, mid-2026

The switching conversation has accelerated because the menu has expanded. Two years ago it was Wegovy or Saxenda. Now there are five distinct paths — injectable semaglutide, oral semaglutide, tirzepatide, liraglutide, and orforglipron — each with different efficacy ceilings, side-effect profiles, and cost structures.

Medicare's GLP-1 coverage kicking in July 1, 2026 will trigger a fresh wave of switches as 65+ patients gain access to medications that were previously cash-only. Foundayo's $149 flat price is pulling in patients who could never have afforded $1,000+/month brand drugs. And the titration process itself is getting more flexible as prescribers accumulate switching experience across molecules.

What to watch during your first month

If you're mid-switch or about to start one, here's what to track and what to flag:

• Weight fluctuations of 2–5 lbs in the first 2 weeks are water, not fat. Don't panic-quit.
• Appetite returning between drugs is pharmacokinetic, not psychological. It passes.
• Nausea peaking around days 3–5 on the new drug is standard. If it's still escalating at week 3, call your prescriber.
• Energy dips during the gap weeks are common. Your body is recalibrating satiety signaling.
• Log everything. Meals, symptoms, injection times, mood. The patterns you notice in those first weeks are exactly the data your doctor needs at the follow-up.

The gap weeks are temporary. The GI reset is manageable. More options usually mean better outcomes for more people. Just don't freelance the transition — every GLP-1 mentioned here is a prescription medication, and switching protocols should run through your prescriber. The detour is short. The map exists. You're not starting from zero.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app